Blood-based molecular cancer test delivers accuracy and specificity levels unsurpassed by other diagnostic methods.

Dave and Florence review the M&A activity for the top 12 highest-grossing medtech companies since 2022 in this months MPO column.

With potential acquirers contacting us every week seeking a company in one of the categories, it’s clear the medical M&A market is still highly active in 2023! For further validation, our frequent flyer miles this year are higher than ever.

Ortoma to present groundbreaking 2D-3D technology for knee and hip joints at the annual ISTA congress in New York 2023.

Will a computer buy your MedTech business or write this article? Contemplating the impact of machine learning (ML) and artificial intelligence (AI) on MedTech & M&A.

Congratulations to MPO on its 20th anniversary! In this article we discuss how M&A will clearly continue to play a key role in the MedTech sector’s future.

Congratulations to our client Ortoma, who following a clinical evaluation of their OTS™ Hip solution, are now working with Johnson & Johnson K.K. to initiate a broad distribution of OTS™ Hip in Japan. 

In the May 2023 edition of Today’s Medical Development Magazine our team discusses reshoring and nearshoring in China and why MedTech players shouldn’t rely solely on production there.

Recent headlines from tech industry giants have spawned an interesting debate about the use of artificial intelligence (AI) in overall society and in healthcare. In our column in the May issue of MPO Magazine, we compiled eight arguments that support AI utilization in healthcare.

MedTech M&A, an industry bank failure, and everything else in-between in our April 2023 column in Today’s Medical Development Magazine.

As the divestitures in Healthcare Fortune 500 companies are making headlines, our team takes the time to discuss the positive impacts they have on MedTech innovation.

In our March 2023 column in Medical Product Outsourcing Magazine we discuss common mistakes MedTech sellers should avoid in order to maximize their M&A value.

The sector cannot totally turn its back on China—it’s too important of a market to overlook. Learn why in our column in Medical Product Outsourcing Magazine.

M&A conference or a CDMO/CMO event? Yes! Read our March column from Today’s Medical Developments Magazine.

In their first column of 2023 in Today’s Medical Developments Magazine, CEO Florence Joffroy-Black and Co-Founder/Managing Director Dave Sheppard share some of the key observations from the 2023 JPM Healthcare Conference.